PT  - JOURNAL ARTICLE
AU  - Shuman, Jill
ED  - Armstrong, Andrew
TI  - Safety and Efficacy of Enzalutamide in Men with Metastatic Prostate Cancer: The PREVAIL Trial
DP  - 2014 Aug 01
TA  - MD Conference Express
PG  - 20--21
VI  - 14
IP  - 14
4099  - http://mdc.sagepub.com/content/14/14/20.2.short
4100  - http://mdc.sagepub.com/content/14/14/20.2.full
AB  - This article presents data from A Safety and Efficacy Study of Oral MDV 3100 [enzalutamide] in Chemotherapy-Naïve Patients With Progressive Metastatic Prostate Cancer [PREVAIL; NCT01212991; Beer TM et al. N Engl J Med 2014]. Enzalutamide, an androgen receptor inhibitor, has been shown to improve overall survival (OS) and radiographic progression-free survival (rPFS) in men with metastatic castrate-resistant prostate cancer (mCRPC) who had received docetaxel therapy [Scher H et al. N Engl J Med 2012]. PREVAIL researchers examined whether enzalutamide could prolong OS and rPFS in men with mCRPC who had progressed on androgen deprivation therapy.